重大事件
即時報告
8-K
2026-07-02
奧洛茲美醫療宣佈營運長離任 高層管理架構調整
AI 繁中摘要
📄 申報類型：8-K
🏢 公司：Halozyme Therapeutics, Inc.（納斯達克代碼：HALO）
📅 報告日期：2026年6月30日
Halozyme Therapeutics 於 2026 年 6 月 30 日宣佈高層管理架構調整，並確認 Senior Vice President、Chief Operating Officer Cortney Caudill 離任。公司感謝 Ms. Caudill 在任期內的貢獻，但未透露繼任人選或具體重組細節。
🔍 重點解讀：
- 高層變動或反映公司戰略調整或內部重組，短期內可能影響市場對管理層穩定性的信心。
- 由於 COO 負責日常營運協調，離職或影響營運效率過渡，惟若公司已制定接班計劃，影響可控。
- 投資者宜關注未來數週内是否公佈繼任安排或進一步管理層變動。
📉 潛在影響：
管理層變動通常被視為不確定因素，尤其欠缺明確接班說明時，股價或出現波動。建議投資者密切留意後續公告，評估對公司長期發展策略的影響。
展開英文正文
halo-20260630FALSE000115903600011590362026-06-302026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 8-K _____________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ________________________ Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 12390 El Camino Real 92130 San Diego(Zip Code) California (Address of principal executive offices) (858) 794-8889 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) ________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par valueHALOThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On June 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced an update to its senior management structure. The company also announced the departure of Cortney Caudill as the Company’s Senior Vice President, Chief Operating Officer. The Company would like to thank Ms. Caudill for her contributions during her tenure with the Company. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: July 2, 2026 By: /s/ Darren Snellgrove Darren Snellgrove Senior Vice President, Chief Financial Officer